Canaccord Genuity Starts Aduro Biotech (ADRO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Broadcom forecasts quarterly revenue below estimates
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
BofA/Merrill Lynch Starts Aduro Biotech (ADRO) at Buy
May 11, 2015 7:23 AM EDTBofA/Merrill Lynch initiated coverage on Aduro Biotech (NASDAQ: ADRO) with a Buy rating.
For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.
Shares of Aduro Biotech closed at $30.85 yesterday.
... MoreWilliam Blair Starts Aduro Biotech (ADRO) at Outperform
May 11, 2015 7:20 AM EDTWilliam Blair initiated coverage on Aduro Biotech (NASDAQ: ADRO) with an Outperform rating.
For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.
Shares of Aduro Biotech closed at $30.85 yesterday.
... MoreLeerink Partners Starts Aduro Biotech (ADRO) at Outperform
May 11, 2015 6:29 AM EDTLeerink Partners initiates coverage on Aduro Biotech (NASDAQ: ADRO) with a Outperform rating and a price target of $48.00.
Analyst Howard Liang commented, "We are initiating coverage of Aduro BioTech (ADRO) with an Outperform rating and price target of $48/share. ADRO is a clinical-stage... More
